Pharmacy World and Science

, Volume 23, Issue 2, pp 70–75 | Cite as

Determinants of change in the intention to use benzodiazepines

  • Rolf van Hulten
  • Aart C. Lodder
  • K. Bart Teeuw
  • Albert Bakker
  • Hubert G. Leufkens
  • Arnold B. Bakker


Objective: To examine attitudes and beliefs associated with changes in the intention to use benzodiazepines during the six‐month period after first benzodiazepine use.Design: Population‐based 6‐month follow‐up with 3 measurement points (baseline, 2 weeks after inclusion, 6 months after inclusion).Setting: Starting or initial benzodiazepine users were included during a period of 4 months from November 1994 in the only pharmacy of a Dutch community of 13,500 people.Measures: Variables proposed by the Model of Planned Behaviour and the Health Belief Model. Drug exposure data from automated pharmacy records.Results: At baseline, the intention to use benzodiazepines was primarily predicted by the perceived norm of the general practitioner regarding benzodiazepine use, and by the participants' own attitudes. After fourteen days, the determinants of change in the intention to use benzodiazepines were the initially perceived norm of the general practitioner and the change in the severity of participants' illnesses. After six months, the change in the severity of the illness and the perceived health benefits of benzodiazepines at the time of inclusion were the main determinants of the change in the intention to use benzodiazepines between the second and third measurement point. The intention to use benzodiazepines showed a decrease during follow‐up. The three intention measures were significant predictors of actual benzodiazepine use during the year following baseline assessment.Conclusion: The study sheds light on interesting determinants of decrease or increase in the intention to use during the six‐month period after first benzodiazepine use.

Benzodiazepines Intentions, attitudes Theory of planned behavior Health belief model Community pharmacy Patents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984;251:375-9.Google Scholar
  2. 2.
    Dunbar GC, Perera MH, Jenner FA. Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br J Psychiatry 1989;155:836-41.Google Scholar
  3. 3.
    King MB. Is there still a role for benzodiazepines in general practice? Br J Gen Pract 1992;42:202-5.Google Scholar
  4. 4.
    Lader M. Benzodiazepine dependence. Int Rev Psychiatry 1989;ZTV182261:149-56.Google Scholar
  5. 5.
    Woods JH, Katz JL, Winger G. Use and abuse of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899-907.Google Scholar
  6. 6.
    Busto U, Bendayan R, Sellers E. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinetics 1989;16:1-26.Google Scholar
  7. 7.
    Cappell H, Busto U, Kay G, Naranjo C, Sellers EMCS. Drug deprivation and reinforcement by diazepam in a dependent population. Psychopharmacology 1987;91:154-60.Google Scholar
  8. 8.
    Smith DE, Wesson DR. Benzodiazepine dependence syndromes. J Psychoactive Drugs 1983;15:85-95.Google Scholar
  9. 9.
    Weintraub M, Singh S, Byrne L, Maharag K, Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991;266:2392-7.Google Scholar
  10. 10.
    Committee on Safety of Medicines. Benzodiazepines, dependence and withdrawal symptoms. Curr probl 1988;21.Google Scholar
  11. 11.
    Knuistingh Neven A, De Graaf WJ, Lucassen PLBJ, Springer MP, Bonsema K, et al. NHG Standaard 'slapeloosheid en slaapmiddelen' (NHG-norm' Insomnia and hypnotics'). ]Huisarts en Wetenschap 1992;35:212-9.Google Scholar
  12. 12.
    Centrale Medische Pharmaceutische Commissie van de Ziekenfondsraad (Central medical pharmaceutical committee of the Council of the Dutch National Health Service). Farmacotherapeutisch Kompas 1996. Amstelveen, the Netherlands: Ziekenfondsraad (Council of the Dutch National Health Service); 1996.Google Scholar
  13. 13.
    Bebbington PE. The content and context of compliance. Int Clin Psychopharmac 1995;9 suppl 5:41-50.Google Scholar
  14. 14.
    Van der Waals FW, Mohrs J, Foets M. Sex differences among recipients of benzodiazepines in Dutch general practice. BMJ 1993;307:363-6.Google Scholar
  15. 15.
    Isacson D, Carsjo K, Bergman U, Blackburn JL. Long-term use of benzodiazepines in a Swedish community: an eight-year follow-up. J Clin Epidemiol 1992,45:429-36.Google Scholar
  16. 16.
    Simon GE, Von Korff M, Barlow W, Pabiniak C, Wagner E. Predictors of chronic benzodiazepine use in a health organization sample. J Clin Epidemiol 1996;49:1067-73.Google Scholar
  17. 17.
    Goldstein MJ. Psychosocial strategies for maximizing the effects of psychotropic medications for schizofrenia and mood disorder. Psychopharmacology Bulletin 1992;28:237-40.Google Scholar
  18. 18.
    Ajzen I, Fishbein M. Understanding attitudes and predicting social behavior. Englewood Cliffs, New Jersey USA: Prentice Hall; 1980.Google Scholar
  19. 19.
    Ajzen I, Madden TJ. Prediction of goal directed behavior: attitudes, intentions and perceived behavior control. J Exp Soc Psychol 1986;22:453-74.Google Scholar
  20. 20.
    Rosenstock IM. Why people use health services. Milbank Mem Fund Quart 1966;44:94-127.Google Scholar
  21. 21.
    Budd RJ, Hughes ICT, Smith JA. Health beliefs and compliance with antipsychotic medication. Br J Clin Psychol 1996;35:393-97.Google Scholar
  22. 22.
    Bond GG, Aiken LS, Somerville SC. The health belief model and adolescents with insulin-dependent diabetes mellitus. Health Psychol 1992;11:190-8.Google Scholar
  23. 23.
    Pellino TA. Relationships between patient attitudes, subjective norms, perceived control, and analgesic use following elective orthopedic surgery. Res Nursing Health 1997;20:97-105.Google Scholar
  24. 24.
    Stafleu A, De Graaf C, Van Staveren WA, Schroots JJF. A review of selected studies assessing social-psychological determinants of fat and cholesterol intake. Food Quality and Preference 1991;3:183-200.Google Scholar
  25. 25.
    Deenen TAM. Patient health-education and self-management: a medical-psychological intervention study on severe asthma and COPD in a high altitude clinic [Thesis]. Amsterdam University, 1996Google Scholar
  26. 26.
    Becker MH, Rosenstock IM. Compliance with a medical regime for asthma: a test of the health belief model. Public Health Reports 1987;93:268-77.Google Scholar
  27. 27.
    Connor M, Norman P. Predicting health behavior: research and practice with social cognition models. Buckingham: Open University Press, 1996.Google Scholar
  28. 28.
    Fishbein M, Ajzen I. Belief, attitude, intention, and behavior: an introduction to theory and research. Reading MA: Addison-Wesley, 1975.Google Scholar
  29. 29.
    Ajzen I. The theory of planned behavior. Organizational Behavior and Human Decision Processes 1991;50:179-211.Google Scholar
  30. 30.
    WHO. Anatomical Therapeutic Chemical (ATC) classification index. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology, 1993.Google Scholar
  31. 31.
    Lau HS, De Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50:619-25.Google Scholar
  32. 32.
    Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariate methods. Boston: PWS-Kent Publishing Company, 1988.Google Scholar
  33. 33.
    Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984;251:375.Google Scholar
  34. 34.
    Salinsky JV, Dore CJ. Characteristics of long-term benzodiazepine users in general practice. J R Coll Gen Pract 1987;37:202-4.Google Scholar
  35. 36.
    Rodrigo EK, King MB, Williams P. Health of long-term benzodiazepine users. BMJ 1988;296:603-6.Google Scholar
  36. 37.
    Van Hulten R, Heerdink ER, Bakker A, Leufkens HG. Benzodiazepine Pathways in the Chronically Ill. Pharmacoepidemiol Drug Saf 1999],8:325-3Google Scholar
  37. 37.
    Mant A, Mattick RP, De Burgh S, Donnelly N, Hall W. Benzodiazepine prescribing in general practice: dispelling some myths. Family Practice 1995;12:37.Google Scholar
  38. 38.
    Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994;48:23-40.Google Scholar
  39. 39.
    Haafkens J. Rituals of silence: Long-term tranquilizer use by women in the Netherlands. A social case study [Thesis]. Amsterdam University, 1997.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Rolf van Hulten
    • 1
  • Aart C. Lodder
    • 1
  • K. Bart Teeuw
    • 1
  • Albert Bakker
    • 1
  • Hubert G. Leufkens
    • 1
  • Arnold B. Bakker
    • 2
  1. 1.Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS)Utrecht UniversityUtrechtThe Netherlands
  2. 2.Department of Social and Organizational PsychologyUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations